Jason Porter, MD, outlines the most significant unaddressed challenges in treating and managing non-small cell lung cancer as the field approaches the American Society of Clinical Oncology's 2024 annual meeting.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More